Niall Murphy

Niall Murphy has over 25 years of experience in the drug delivery, biopharmaceutical, and medical device industries, serving in a variety of senior finance roles. Prior to joining Graybug, he served as Director, Financial Planning & Analysis, at Corium, a publicly traded, commercial-stage biopharmaceutical company specializing in the development of transdermal drug delivery systems. Prior to that, he served as Vice President, Finance & Administration, at Fluxion Biosciences, a privately held medical device company specializing in live-cell analysis tools. Earlier in his career, Niall held senior leadership roles in Finance at Invuity (acquired by Stryker in 2018), Codexis (IPO in April 2010), National Reproductive Medical Centers (acquired by Matria Healthcare), Alere Medical (acquired by Inverness Medical Innovations), and Eos Biotechnology (acquired by PDL Biopharma). Before his industry experience, Niall worked for Arthur Andersen in their tax practice and audit practice. He holds a Bachelor of Science degree in Chemical Engineering from the University of British Columbia, an MBA from the University of California, Davis, and is a licensed CPA (active status).